Possible therapeutic effects of myxobacterial metabolites on type I Gaucher disease

Kim, Sung-Jo; Kang, Sunyang; Kim, June-Bum

doi:10.1016/j.gene.2012.05.036

Cited by 2 publications

(2 citation statements)

References 19 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid extraction and GluCer separation were performed as described in a previous article. 9) Densitometric analysis was carried out to measure GluCer levels with TINA 2.0 software (Raytest Isotopenmessgeräte GmbH, Straubenhardt, Germany).…”

Section: Methodsmentioning

confidence: 99%

Anti-apoptotic and Beneficial Metabolic Activities of Resveratrol in Type II Gaucher Disease

Yoo

Kim

2015

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Gaucher disease (GD) is one of the most common lysosomal storage disorders and is caused by an inherited deficiency in glucocerebrosidase. Resveratrol is a phytoalexin that has many beneficial activities, including anti-oxidant, anti-apoptotic, and neuroprotective effects. The aim of this study was to determine if resveratrol has a therapeutic effect on primary fibroblast cells derived from a patient with type II GD. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were performed to determine the effect of resveratrol on cell viability. The expression patterns of apoptosis-inducing factor (AIF), Bcl-2-associated X protein (Bax), caspase-3, acetyl-coenzyme A acetyltransferase 1 (ACAT1), E3-binding protein (E3BP), and citrate synthase (CS) were evaluated by Western blotting to characterize the effect of resveratrol treatment on GD cells. TLC was performed to determine glucosylceramide levels in resveratrol-treated GD cells. Resveratrol increased GD cell viability compared to untreated control cells. Further, resveratrol treatment dose-dependently decreased the apoptotic factors AIF, Bax, and cleaved caspase-3 levels, whereas ACAT1, E3BP, and CS expression dose-dependently increased. TLC analysis showed reduced levels of intracellular glucosylceramides in resveratrol-treated GD cells. These findings demonstrate that resveratrol can reduce cellular stress resulting from glucosylceramide accumulation, and suggest that resveratrol should be studied further as a novel therapeutic agent for GD.

show abstract

Section: Methodsmentioning

confidence: 99%

Anti-apoptotic and Beneficial Metabolic Activities of Resveratrol in Type II Gaucher Disease

Yoo

Kim

2015

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

show abstract

“…Quantitative changes in GluCer levels for cells treated with resveratrol or DMSO (vehicle control) were evaluated by thin‐layer chromatography (TLC). Lipid extraction and GluCer separation were carried out as described in our previous article (Kim et al, ). Densitometric analysis was performed to examine GluCer levels with TINA 2.0 software (Raytest Isotopenmessgeräte GmbH).…”

Section: Methodsmentioning

confidence: 99%

Therapeutic Potential of Resveratrol in Type I Gaucher Disease

Seo

Kim

2015

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

Resveratrol is a natural polyphenol that possesses various beneficial properties, such as anti-inflammatory, anti-oxidant, and neuroprotective effects. This study evaluated the potential therapeutic effects of resveratrol on primary fibroblasts derived from a patient with Gaucher disease. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were carried out to determine whether resveratrol affects cell survival. Changes in the expression levels of apoptosis-inducing factor (AIF), Bax, cleaved caspase-3, acetyl-coenzyme A acetyltransferase 1 (ACAT1), E3-binding protein (E3BP), and citrate synthase (CS) were determined by western immunoblot to characterize the effect of resveratrol treatment on Gaucher disease cells. Intracellular glucosylceramide levels in resveratrol-treated patient cells were determined by thin-layer chromatography (TLC). Resveratrol significantly increased the viability of patient cells in comparison with that of control cells. After exposure to resveratrol, expression levels of the apoptotic factors AIF, Bax, and cleaved caspase-3 dose-dependently decreased, while those of ACAT1, E3BP, and CS dose-dependently increased. TLC showed a significant decrease in glucosylceramide levels in patient cells treated with resveratrol. These findings demonstrate that resveratrol can reduce apoptotic events and glucosylceramide levels in Gaucher disease cells, and that it merits further research as a possible therapeutic compound.

show abstract

Possible therapeutic effects of myxobacterial metabolites on type I Gaucher disease

Cited by 2 publications

References 19 publications

Anti-apoptotic and Beneficial Metabolic Activities of Resveratrol in Type II Gaucher Disease

Anti-apoptotic and Beneficial Metabolic Activities of Resveratrol in Type II Gaucher Disease

Therapeutic Potential of Resveratrol in Type I Gaucher Disease

Contact Info

Product

Resources

About